This site is intended for health professionals only
Sunday 23 October 2016 Instagram
Share |

NICE recommends once-weekly diabetes drug

NICE recommends once-weekly diabetes drug


The NHS drugs watchdog has recommended a once-weekly injection for patients with type 2 diabetes.

Prolonged release exentide is said to offer suitable patients the potential to improve blood glucose control in a once-weekly injection with the added benefit of weight loss for some patients.

It also means the "injection burden" is reduced from once- or twice-daily to once-weekly, which is hoped to increase compliance among type 2 diabetes patients.

The National Institute for Health and Clinical Excellence's (NICE) recommendation is conditional on the drug being used in combination with metformin and a sulphonylurea, or metformin and a thiazolidinedionei.

Eligible patients must also have:

• A BMI of 35 kg/m2 or higher in those of European family origin, or

• A BMI below 35 kg/m2, and therapy with insulin would have significant occupational implications

"2.25 million people in the UK are now affected by type 2 diabetes, therefore it is important that there are a range of effective treatment options, such as prolonged-release exenatide, available to them," said Professor Carole Longson, Health Technology Evaluation Centre Director at NICE.

"Type 2 diabetes is a serious, progressive disease; I am sure all those affected will welcome this positive final draft recommendation."

NICE final guidance on the use of prolonged-release exenatide is expected to be published in February 2012.

Ads by Google

You are leaving

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?